LANDSCAPE: An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR).

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Whole Brain ◽

P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.

10.1158/0008-5472.sabcs11-p1-06-12 ◽

2011 ◽

Author(s):

J-Y Pierga ◽

C Cropet ◽

P Tresca ◽

F Dalenc ◽

G Romieu ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Abstract P2-16-02: Bevacizumab, etoposide, and cisplatin (BEEP) is highly effective in brain metastases of HER2 positive breast cancer progressing from whole brain radiotherapy - Subgroup analysis of a multi-center phase II study

10.1158/0008-5472.sabcs13-p2-16-02 ◽

2013 ◽

Author(s):

Y-S Lu ◽

W-W Chen ◽

C-H Lin ◽

D-C Yeh ◽

L-M Tseng ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Subgroup Analysis ◽

Phase Ii Study ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Brain Radiotherapy ◽

Positive Breast Cancer

Abstract OT1-04-03: Randomized phase II study of induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases (A-PLUS)

10.1158/1538-7445.sabcs16-ot1-04-03 ◽

2017 ◽

Author(s):

Y-S Lu ◽

L-M Tseng ◽

J-C Yu ◽

K-M Rau ◽

T-Y Chao ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastases ◽

Phase Ii ◽

Phase Ii Study ◽

Whole Brain ◽

Brain Radiotherapy ◽

Randomized Phase Ii

Safety of Herceptin monotherapy administered on a 3-weekly schedule: Preliminary data from a phase II study in women with HER2-positive metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(02)80299-4 ◽

2002 ◽

Vol 38 (11) ◽

pp. S95

Author(s):

J Baselga

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Preliminary Data ◽

Phase Ii Study ◽

Metastatic Breast ◽

Weekly Schedule ◽

Her2 Positive

Metronomic oral Vinorelbine and Temozolomide, after whole brain radiotherapy, for the treatment of breast cancer patients with brain metastasis. A Phase II study

European Journal of Cancer Supplements ◽

10.1016/j.ejcsup.2008.06.032 ◽

2008 ◽

Vol 6 (14) ◽

pp. 116

Author(s):

Liliana Montella ◽

Raffaele Addeo ◽

Gino Leo ◽

Carmine De Rosa ◽

Gregorio Cennamo ◽

...

Keyword(s):

Breast Cancer ◽

Brain Metastasis ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Breast Cancer Patients ◽

Oral Vinorelbine ◽

Whole Brain ◽

SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdx365.084 ◽

2017 ◽

Vol 28 ◽

pp. v106-v107 ◽

Cited By ~ 3

Author(s):

P. Villagrasa Gonzalez ◽

A. Prat ◽

M. Oliveira ◽

L. de la Pena ◽

X. Gonzalez ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive

232 Final Results of a Phase II Study of the Combination of Oral Vinorelbine (NVBo), Capecitabine (X) and Trastuzumab (H) in HER2-positive Metastatic Breast Cancer (MBC)

European Journal of Cancer ◽

10.1016/s0959-8049(12)70300-3 ◽

2012 ◽

Vol 48 ◽

pp. S110

Author(s):

L. Petruzelka ◽

V. Ganju ◽

P.F. Conte ◽

N. Tubiana-Mathieu ◽

F. Majois ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive ◽

Oral Vinorelbine

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Breast Cancer Research and Treatment ◽

10.1007/s10549-017-4203-y ◽

2017 ◽

Vol 163 (3) ◽

pp. 507-515 ◽

Cited By ~ 3

Author(s):

Konstantinos Tryfonidis ◽

◽

S. Marreaud ◽

H. Khaled ◽

B. De Valk ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Extracellular Domain ◽

Cardiac Safety ◽

Her2 Positive ◽

Serial Serum

Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy

Annals of Oncology ◽

10.1093/annonc/mdx365.015 ◽

2017 ◽

Vol 28 ◽

pp. v81

Author(s):

N.M. Iyengar ◽

L.M. Smyth ◽

D. Lake ◽

A. Gucalp ◽

J.C. Singh ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Her2 Positive

P4-17-12: Analysis of Predictive and Prognostic Factors for Metastatic Breast Cancer Patients with Brain Metastasis Treated by Whole Brain Radiotherapy.

10.1158/0008-5472.sabcs11-p4-17-12 ◽

2011 ◽

Author(s):

IH Park ◽

KS Lee ◽

KH Shin ◽

J Ro

Keyword(s):

Breast Cancer ◽

Prognostic Factors ◽

Brain Metastasis ◽

Cancer Patients ◽

Metastatic Breast ◽

Breast Cancer Patients ◽

Whole Brain ◽